RS 83277

synthetic peptide derived from C-reactive protein; significantly enhances tumoricidal activity of both monocytes & macrophages; has a role as a biological response modifier in cancer therapy

Also Known As:

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 01/01/1994 - "Results demonstrated that the capacity of RS-83277 MLV to inhibit tumor metastases and prolong survival was significantly augmented by combination with 10,000 U/day IL-2 i.p. " 01/01/1994 - "The present study evaluated the therapeutic and immunomodulatory effects of administering CRP peptide RS-83277 MLV simultaneously with low-dose recombinant interleukin-2 (IL-2) to C57Bl/6 mice bearing established pulmonary metastases of fibrosarcoma T241. "
2.	Fibrosarcoma 01/01/1994 - "The present study evaluated the therapeutic and immunomodulatory effects of administering CRP peptide RS-83277 MLV simultaneously with low-dose recombinant interleukin-2 (IL-2) to C57Bl/6 mice bearing established pulmonary metastases of fibrosarcoma T241. "
3.	Neoplasms (Cancer) 01/01/1994 - "Results demonstrated that the capacity of RS-83277 MLV to inhibit tumor metastases and prolong survival was significantly augmented by combination with 10,000 U/day IL-2 i.p. " 01/01/1993 - "These data suggest a role for synthetic CRP peptide, RS-83277, as a novel biological response modifier in cancer therapy."

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Interleukin-2 (IL2)
3.	Immunologic Factors (Immunomodulators)

Related Therapies and Procedures

1.	Therapeutics